Systemic Resolvin E1 (RvE1) Treatment Does Not Ameliorate the Severity of Collagen-Induced Arthritis (CIA) in Mice: A Randomized, Prospective, and Controlled Proof of Concept Study

Specialized proresolving mediators (SPRM), which arise from n-3 long-chain polyunsaturated fatty acids (n-3FA), promote resolution of inflammation and may help to prevent progression of an acute inflammatory response into chronic inflammation in patients with arthritis. Thus, this study is aimed at...

Full description

Saved in:
Bibliographic Details
Main Authors: Rafael Scaf de Molon, Rogier M. Thurlings, Birgitte Walgreen, Monique M. Helsen, Peter M. van der Kraan, Joni Augusto Cirelli, Marije I. Koenders
Format: Article
Language:English
Published: Wiley 2019-01-01
Series:Mediators of Inflammation
Online Access:http://dx.doi.org/10.1155/2019/5689465
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832545614223638528
author Rafael Scaf de Molon
Rogier M. Thurlings
Birgitte Walgreen
Monique M. Helsen
Peter M. van der Kraan
Joni Augusto Cirelli
Marije I. Koenders
author_facet Rafael Scaf de Molon
Rogier M. Thurlings
Birgitte Walgreen
Monique M. Helsen
Peter M. van der Kraan
Joni Augusto Cirelli
Marije I. Koenders
author_sort Rafael Scaf de Molon
collection DOAJ
description Specialized proresolving mediators (SPRM), which arise from n-3 long-chain polyunsaturated fatty acids (n-3FA), promote resolution of inflammation and may help to prevent progression of an acute inflammatory response into chronic inflammation in patients with arthritis. Thus, this study is aimed at determining whether systemic RvE1 treatment reduces arthritis onset and severity in murine collagen-induced arthritis (CIA) and spontaneous cytokine production by human rheumatoid arthritis (RA) synovial explants. 10-week-old DBA1/J male mice were subjected to CIA and treated systemically with 0.1 μg RvE1, 1 μg RvE1, 5 mg/kg anti-TNF (positive control group), PBS (negative control group), or with a combination of 1 μg of RvE1 plus 5 mg/kg anti-TNF using prophylactic or therapeutic strategies. After CIA immunization, mice were treated twice a week by RvE1 or anti-TNF for 10 days. Arthritis development was assessed by visual scoring of paw swelling and histology of ankle joints. Moreover, human RA synovial explants were incubated with 1 nM, 10 nM, or 100 nM of RvE1, and cytokine levels (IL-1β, IL-6, IL-8, IL-10, INF-γ, and TNF-α) were measured using Luminex bead array. CIA triggered significant inflammation in the synovial cavity, proteoglycan loss, and cartilage and bone destruction in the ankle joints of mice. Prophylactic and therapeutic RvE1 regimens did not ameliorate CIA incidence and severity. Anti-TNF treatment significantly abrogated signs of joint inflammation, bone erosion, and proteoglycan depletion, but additional RvE1 treatment did not further reduce the anti-TNF-mediated suppression of the disease. Treatment with different concentrations of RvE1 did not decrease the expression of proinflammatory cytokines in human RA synovial explants in the studied conditions. Collectively, our findings demonstrated that RvE1 treatment was not an effective approach to treat CIA in DBA1/J mice in both prophylactic and therapeutic strategies. Furthermore, no effects were noticed when human synovial explants were incubated with different concentrations of RvE1.
format Article
id doaj-art-f4702047da6c42b485c2bf40d388f583
institution Kabale University
issn 0962-9351
1466-1861
language English
publishDate 2019-01-01
publisher Wiley
record_format Article
series Mediators of Inflammation
spelling doaj-art-f4702047da6c42b485c2bf40d388f5832025-02-03T07:25:17ZengWileyMediators of Inflammation0962-93511466-18612019-01-01201910.1155/2019/56894655689465Systemic Resolvin E1 (RvE1) Treatment Does Not Ameliorate the Severity of Collagen-Induced Arthritis (CIA) in Mice: A Randomized, Prospective, and Controlled Proof of Concept StudyRafael Scaf de Molon0Rogier M. Thurlings1Birgitte Walgreen2Monique M. Helsen3Peter M. van der Kraan4Joni Augusto Cirelli5Marije I. Koenders6Department of Diagnosis and Surgery, School of Dentistry at Araraquara, Sao Paulo State University-UNESP, Araraquara, SP, BrazilDepartment of Rheumatology, Radboud University Medical Center, 6500 HB Nijmegen, NetherlandsDepartment of Rheumatology, Radboud University Medical Center, 6500 HB Nijmegen, NetherlandsDepartment of Rheumatology, Radboud University Medical Center, 6500 HB Nijmegen, NetherlandsDepartment of Rheumatology, Radboud University Medical Center, 6500 HB Nijmegen, NetherlandsDepartment of Diagnosis and Surgery, School of Dentistry at Araraquara, Sao Paulo State University-UNESP, Araraquara, SP, BrazilDepartment of Rheumatology, Radboud University Medical Center, 6500 HB Nijmegen, NetherlandsSpecialized proresolving mediators (SPRM), which arise from n-3 long-chain polyunsaturated fatty acids (n-3FA), promote resolution of inflammation and may help to prevent progression of an acute inflammatory response into chronic inflammation in patients with arthritis. Thus, this study is aimed at determining whether systemic RvE1 treatment reduces arthritis onset and severity in murine collagen-induced arthritis (CIA) and spontaneous cytokine production by human rheumatoid arthritis (RA) synovial explants. 10-week-old DBA1/J male mice were subjected to CIA and treated systemically with 0.1 μg RvE1, 1 μg RvE1, 5 mg/kg anti-TNF (positive control group), PBS (negative control group), or with a combination of 1 μg of RvE1 plus 5 mg/kg anti-TNF using prophylactic or therapeutic strategies. After CIA immunization, mice were treated twice a week by RvE1 or anti-TNF for 10 days. Arthritis development was assessed by visual scoring of paw swelling and histology of ankle joints. Moreover, human RA synovial explants were incubated with 1 nM, 10 nM, or 100 nM of RvE1, and cytokine levels (IL-1β, IL-6, IL-8, IL-10, INF-γ, and TNF-α) were measured using Luminex bead array. CIA triggered significant inflammation in the synovial cavity, proteoglycan loss, and cartilage and bone destruction in the ankle joints of mice. Prophylactic and therapeutic RvE1 regimens did not ameliorate CIA incidence and severity. Anti-TNF treatment significantly abrogated signs of joint inflammation, bone erosion, and proteoglycan depletion, but additional RvE1 treatment did not further reduce the anti-TNF-mediated suppression of the disease. Treatment with different concentrations of RvE1 did not decrease the expression of proinflammatory cytokines in human RA synovial explants in the studied conditions. Collectively, our findings demonstrated that RvE1 treatment was not an effective approach to treat CIA in DBA1/J mice in both prophylactic and therapeutic strategies. Furthermore, no effects were noticed when human synovial explants were incubated with different concentrations of RvE1.http://dx.doi.org/10.1155/2019/5689465
spellingShingle Rafael Scaf de Molon
Rogier M. Thurlings
Birgitte Walgreen
Monique M. Helsen
Peter M. van der Kraan
Joni Augusto Cirelli
Marije I. Koenders
Systemic Resolvin E1 (RvE1) Treatment Does Not Ameliorate the Severity of Collagen-Induced Arthritis (CIA) in Mice: A Randomized, Prospective, and Controlled Proof of Concept Study
Mediators of Inflammation
title Systemic Resolvin E1 (RvE1) Treatment Does Not Ameliorate the Severity of Collagen-Induced Arthritis (CIA) in Mice: A Randomized, Prospective, and Controlled Proof of Concept Study
title_full Systemic Resolvin E1 (RvE1) Treatment Does Not Ameliorate the Severity of Collagen-Induced Arthritis (CIA) in Mice: A Randomized, Prospective, and Controlled Proof of Concept Study
title_fullStr Systemic Resolvin E1 (RvE1) Treatment Does Not Ameliorate the Severity of Collagen-Induced Arthritis (CIA) in Mice: A Randomized, Prospective, and Controlled Proof of Concept Study
title_full_unstemmed Systemic Resolvin E1 (RvE1) Treatment Does Not Ameliorate the Severity of Collagen-Induced Arthritis (CIA) in Mice: A Randomized, Prospective, and Controlled Proof of Concept Study
title_short Systemic Resolvin E1 (RvE1) Treatment Does Not Ameliorate the Severity of Collagen-Induced Arthritis (CIA) in Mice: A Randomized, Prospective, and Controlled Proof of Concept Study
title_sort systemic resolvin e1 rve1 treatment does not ameliorate the severity of collagen induced arthritis cia in mice a randomized prospective and controlled proof of concept study
url http://dx.doi.org/10.1155/2019/5689465
work_keys_str_mv AT rafaelscafdemolon systemicresolvine1rve1treatmentdoesnotamelioratetheseverityofcollageninducedarthritisciainmicearandomizedprospectiveandcontrolledproofofconceptstudy
AT rogiermthurlings systemicresolvine1rve1treatmentdoesnotamelioratetheseverityofcollageninducedarthritisciainmicearandomizedprospectiveandcontrolledproofofconceptstudy
AT birgittewalgreen systemicresolvine1rve1treatmentdoesnotamelioratetheseverityofcollageninducedarthritisciainmicearandomizedprospectiveandcontrolledproofofconceptstudy
AT moniquemhelsen systemicresolvine1rve1treatmentdoesnotamelioratetheseverityofcollageninducedarthritisciainmicearandomizedprospectiveandcontrolledproofofconceptstudy
AT petermvanderkraan systemicresolvine1rve1treatmentdoesnotamelioratetheseverityofcollageninducedarthritisciainmicearandomizedprospectiveandcontrolledproofofconceptstudy
AT joniaugustocirelli systemicresolvine1rve1treatmentdoesnotamelioratetheseverityofcollageninducedarthritisciainmicearandomizedprospectiveandcontrolledproofofconceptstudy
AT marijeikoenders systemicresolvine1rve1treatmentdoesnotamelioratetheseverityofcollageninducedarthritisciainmicearandomizedprospectiveandcontrolledproofofconceptstudy